Blackhills Diagnostic Resources (BDR)
Private Company
Funding information not available
Overview
BDR is a privately held, revenue-generating diagnostics company with a fully integrated model from R&D to post-sale service. Its core expertise lies in molecular diagnostics, particularly in HLA genotyping for transplant compatibility and genetic testing for rare diseases like Huntington's. The company is ISO 13485:2016 and CE IVDR certified, positioning it as a specialized, compliant player in the European IVD market. Its strategy combines proprietary assay development with bioinformatics software to serve clinical laboratories.
Technology Platform
Molecular diagnostics platform utilizing Real-Time PCR (TaqMan), Capillary Electrophoresis (Fragment Analysis), proprietary bioinformatics software, and Next-Generation Sequencing (NGS) for genetic analysis.
Opportunities
Risk Factors
Competitive Landscape
BDR competes in specialized niches against other focused molecular diagnostic companies and divisions of larger IVD conglomerates (e.g., Thermo Fisher, Qiagen, Immucor). Its competitive advantage lies in its deep specialization, fully integrated model, proprietary software, and early compliance with the stringent EU IVDR, which may pose challenges for some competitors.